Open Access Green as soon as Postprint is submitted to ZB.
Hyperthermia adds to chemotherapy.
Eur. J. Cancer 44, 2546-2554 (2008)
The hallmarks of hyperthermia and its pleotropic effects are in favour of its combined use with chemotherapy. Preclinical research reveals that for heat killing and synergistic effects the thermal dose is most critical. Thermal enhancement of drug cytotoxicity is accompanied by cellular death and necrosis without increasing its oncogenic potential. The induction of genetically defined stress responses can deliver danger signals to activate the host's immune system. The positive results of randomised trials have definitely established hyperthermia in combination with chemotherapy as a novel clinical modality for the treatment of cancer. Hyperthermia targets the action of chemotherapy within the heated tumour region without affecting systemic toxicity. In specific clinical settings regional hyperthermia (RHT) or hyperthermic perfusion has proved its value and deserve a greater focus and investigation in other malignancies. In Europe, more specialised centres should be created and maintained as network of excellence for hyperthermia in the field of oncology.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
4.454
1.520
214
311
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Hyperthermia; Chemotherapy; HSP; Immunology; Liposomes; HIPEC; ILP
Language
english
Publication Year
2008
HGF-reported in Year
0
ISSN (print) / ISBN
0959-8049
e-ISSN
1879-0852
Journal
European Journal of Cancer
Quellenangaben
Volume: 44,
Issue: 17,
Pages: 2546-2554
Publisher
Elsevier
Reviewing status
Peer reviewed
Institute(s)
CCG Tumor Therapy with Hyperthermia (IMI-KTH)
POF-Topic(s)
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Research field(s)
Immune Response and Infection
PSP Element(s)
G-521100-001
Erfassungsdatum
2008-12-31